Edimara S Reis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6433360/publications.pdf

Version: 2024-02-01

52	4,369	159358	182168
papers	citations	30 h-index	51 g-index

54	54	54	5508
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nature Cancer, 2021, 2, 218-232.	5.7	34
2	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	5.8	29
3	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica, 2020, 105, e57-e60.	1.7	17
4	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 2020, 214, 108391.	1.4	16
5	New insights into the immune functions of complement. Nature Reviews Immunology, 2019, 19, 503-516.	10.6	281
6	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology, 2019, 10, 406.	2.2	60
7	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. Clinical Immunology, 2019, 198, 102-105.	1.4	11
8	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock, 2019, 51, 78-87.	1.0	34
9	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Frontiers in Immunology, 2019, 10, 3029.	2.2	6
10	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
11	Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2018, 18, 5-18.	10.6	279
12	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. Cancer Cell, 2018, 34, 531-533.	7.7	4
13	Safety profile after prolonged C3 inhibition. Clinical Immunology, 2018, 197, 96-106.	1.4	38
14	Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis. Circulation, 2018, 138, 1720-1735.	1.6	77
15	Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. Thrombosis and Haemostasis, 2018, 118, 1484-1487.	1.8	7
16	Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis. Journal of Proteome Research, 2018, 17, 3153-3175.	1.8	24
17	New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. Journal of Medicinal Chemistry, 2018, 61, 6153-6162.	2.9	23
18	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305

#	Article	IF	Citations
19	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
20	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology, 2017, 6, e1326442.	2.1	48
21	Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. American Journal of Physiology - Renal Physiology, 2017, 312, F516-F532.	1.3	64
22	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1041-1042, 19-26.	1.2	8
23	Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Molecular Therapy - Methods and Clinical Development, 2017, 6, 207-215.	1.8	33
24	Novel mechanisms and functions of complement. Nature Immunology, 2017, 18, 1288-1298.	7.0	364
25	Complement component C3aR constitutes a novel regulator for chick eye morphogenesis. Developmental Biology, 2017, 428, 88-100.	0.9	8
26	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 1046-1057.	0.8	14
27	Complement in disease: a defence system turning offensive. Nature Reviews Nephrology, 2016, 12, 383-401.	4.1	427
28	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 2016, 171, 32-35.	1.4	23
29	High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. Molecular Cancer Research, 2016, 14, 953-965.	1.5	38
30	Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration. Journal of Immunology, 2016, 197, 2500-2508.	0.4	22
31	Complement component C3 â€“ The â€œSwiss Army Knifeâ€•of innate immunity and host defense. Immunological Reviews, 2016, 274, 33-58.	2.8	313
32	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology, 2015, 220, 476-482.	0.8	58
33	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. Journal of Immunology, 2015, 194, 3305-3316.	0.4	23
34	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
35	Conjugation to Albuminâ€Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. ChemMedChem, 2014, 9, 2223-2226.	1.6	13
36	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 2014, 123, 2094-2101.	0.6	172

#	Article	IF	Citations
37	The Evolution and Appearance of C3 Duplications in Fish Originate an Exclusive Teleost c3 Gene Form with Anti-Inflammatory Activity. PLoS ONE, 2014, 9, e99673.	1.1	54
38	CMAP: Complement Map Database. Bioinformatics, 2013, 29, 1832-1833.	1.8	26
39	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology, 2013, 218, 496-505.	0.8	129
40	Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nature Communications, 2013, 4, 2312.	5.8	80
41	A sweet spot to control complement-induced inflammation. Nature Medicine, 2012, 18, 1340-1341.	15.2	6
42	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. Journal of Immunology, 2012, 189, 4797-4805.	0.4	50
43	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. Journal of Immunology, 2012, 189, 5442-5448.	0.4	100
44	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology, 2012, 217, 1097-1105.	0.8	39
45	Sleep and circadian rhythm regulate circulating complement factors and immunoregulatory properties of C5a. Brain, Behavior, and Immunity, 2011, 25, 1416-1426.	2.0	75
46	C5a receptorâ€deficient dendritic cells promote induction of Treg and Th17 cells. European Journal of Immunology, 2010, 40, 710-721.	1.6	113
47	The role of the anaphylatoxins in health and disease. Molecular Immunology, 2009, 46, 2753-2766.	1.0	582
48	Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Molecular Immunology, 2008, 45, 1693-1702.	1.0	44
49	Impaired dendritic cell differentiation and maturation in the absence of C3. Molecular Immunology, 2008, 45, 1952-1962.	1.0	26
50	A regulatory role for the C5a anaphylatoxin in TH17 cell differentiation. Molecular Immunology, 2008, 45, 4108.	1.0	0
51	Complement components, regulators and receptors are produced by human monocyte-derived dendritic cells. Immunobiology, 2007, 212, 151-157.	0.8	35
52	Nonsense-codon-mediated decay in human hereditary complement C3 deficiency. Immunogenetics, 2004, 55, 667-673.	1.2	14